{"id":3677,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amantadine-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amantadine-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amantadine-hydrochloride-txt\/","title":{"rendered":"Amantadine hydrochloride.txt"},"content":{"rendered":"

Amantadine hydrochloride<\/h1>\n

CLINICAL USE <\/H3><\/p>\n
  • Parkinson\u2019s disease (but not drug induced\n

    extrapyramidal symptoms)<\/p>\n

  • Post-herpetic neuralgia\n
  • Prophylaxis and treatment of influenza A\n

    DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • Parkinson\u2019s disease: 100 mg once a day,\n

    increased after one week to 100\u2013200 mg
    \ntwice a day<\/p>\n

  • Post-herpetic neuralgia: 100 mg twice a\n

    day for 14 days<\/p>\n

  • Influenza A: treatment \u2013 100 mg once a\n

    day for 4\u20135 days; prophylaxis \u2013 100 mg
    \nonce a day
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n187.7\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n67\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n90\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n5\u201310\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n15\/500
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n35\u201350 100 mg every 24 hours
    \n15\u201335 100 mg every 48\u201372 hours
    \n<15
    \n100 mg every 7 days
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in
    \nGFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in
    \nGFR <10 mL\/min
    \n
  • HDF\/high flux &nbsp :
    \nUnknown dialysability. Dose as in
    \nGFR<15 mL\/min
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nGFR=15\u201335 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Memantine: increased risk of CNS\n

    toxicity \u2013 avoid concomitant use; effects of
    \namantadine possibly enhanced
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Peripheral oedema may occur in some\n

    patients; should be considered when
    \nthe drug is prescribed for those with
    \ncongestive heart failure<\/p>\n

  • Side effects are often mild and transient;\n

    usually appear within 2\u20134 days of
    \ntreatment and disappear 24\u201348 hours after
    \ndiscontinuation of the drug<\/p>\n

  • Due to extensive tissue binding, <5% of a\n

    dose is removed by a 4 hour haemodialysis
    \nsession<\/p>\n

  • A reduction in creatinine clearance to\n

    40 mL\/min may result in a 5-fold increase
    \nin elimination half-life<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amantadine hydrochloride CLINICAL USE Parkinson\u2019s disease (but not drug induced<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3677","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3677"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3677\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}